There is a lesson to be learned in the CYDY share

There is a lesson to be learned in the CYDY share count comparison. Courts have determined CYDY officers inappropriately awarded themselves shares. Not once but twice. Unbelievable.

Management needs to reward shareholders before enriching themselves. Better yet we should get rewarded together.

But SeekingAlfa, GNBT has spent over a year getting the pre-clinical IND done and accepted, the work done and we still don't have the IND app done yet. I sure hope Generex chose more wisely than CYDY did choosing Amarex to be their CRO to manage this vaccine trial.

I would love to see progress Generex/NGIO. Today would be great.